Price alert —
Sign in to get a one-time email the moment BBIO crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · BBIO
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.2B | $-0.2B | $-0.1B | $-0.2B | -84.3% | -54.5% |
| 2025-12-31 | $0.2B | $-0.2B | $-0.1B | $-0.1B | -125.1% | -83.3% |
| 2025-09-30 | $0.1B | $-0.2B | $-0.1B | $-0.1B | -151.4% | -113.0% |
| 2025-06-30 | $0.1B | $-0.2B | $-0.1B | $-0.1B | -164.5% | -120.7% |
| 2025-03-31 | $0.1B | $-0.2B | $-0.1B | $-0.2B | -143.5% | -89.0% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare BBIO vs peers
Line BBIO up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with BBIO
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | -0.84 | -0.62 | -36.2% | -0.1% |
| 2026-02-24 | -0.94 | -0.62 | -50.6% | -2.6% |
| 2025-10-29 | -0.72 | -0.78 | +7.7% | -4.9% |
| 2025-08-05 | -0.95 | -0.60 | -57.1% | -8.9% |
| 2025-04-29 | -0.99 | -1.00 | +0.9% | +5.3% |
| 2025-02-20 | -1.37 | -1.09 | -26.1% | +0.1% |
| 2024-11-12 | -1.08 | -0.86 | -25.1% | +0.7% |
| 2024-08-01 | -1.01 | -0.94 | -7.2% | +0.0% |
| 2024-05-02 | -0.12 | -0.54 | +77.0% | +0.3% |
| 2024-02-22 | -0.96 | -0.80 | -20.1% | +1.2% |
| 2023-11-02 | -1.08 | -0.89 | -21.6% | +7.1% |
| 2023-08-03 | -0.96 | -0.87 | -9.9% | -2.6% |
| 2023-05-04 | -0.90 | -0.83 | -7.7% | +1.3% |
| 2023-02-23 | -0.87 | -0.94 | +7.3% | -0.2% |
| 2022-11-03 | -0.89 | -1.01 | +11.2% | -0.2% |
| 2022-08-04 | -0.75 | -0.86 | +13.7% | +12.1% |
| 2022-05-05 | -1.19 | -1.10 | -8.8% | -10.8% |
| 2022-02-24 | -1.01 | -0.91 | -11.5% | -1.2% |
| 2021-11-04 | -1.06 | -0.91 | -16.4% | +3.8% |
| 2021-08-05 | -0.66 | -0.89 | +26.0% | -3.6% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| BBIO ★ | $16B | — | 137.9 | 27.5 | -35.1 | -7.0 | 95.1% | 66.8% | — | -1.99% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 47.3%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 14,207,757 | 7.25% |
| Kohlberg Kravis Roberts & Co. L.P. | 13,260,971 | 6.77% |
| Janus Henderson Group PLC | 13,179,013 | 6.73% |
| Viking Global Investors, L.P. | 11,842,434 | 6.05% |
| Farallon Capital Management LLC | 9,365,463 | 4.78% |
| Vanguard Portfolio Management LLC | 8,080,573 | 4.13% |
| Vanguard Capital Management LLC | 7,759,495 | 3.96% |
| Aisling Capital Management LP | 5,089,611 | 2.60% |
| State Street Corporation | 4,934,320 | 2.52% |
| Geode Capital Management, LLC | 4,918,030 | 2.51% |
Insider activity · 90d
0 buys / 4 sells · ratio 0.0 · Finnhub
- Ellis Andrea M 17,167
- Ellis Andrea SELL 22,579 @ $84.00
- Ellis Andrea M 39,746 @ $16.75
- Cook Jennifer E. M 0
- Cook Jennifer E. M 0
- Cook Jennifer E. M 0
- Cook Jennifer E. SELL 8,383 @ $90.00
- Cook Jennifer E. SELL 120,805 @ $84.00
- Cook Jennifer E. M 156,972 @ $16.75
- Cook Jennifer E. M 139,805 @ $29.00
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-13 | FORM 4 | view · |
| 4 | 2026-07-13 | FORM 4 | view · |
| 8-K | 2026-07-02 | 8-K | view · |
| 8-K | 2026-06-26 | 8-K | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-24 | FORM 4 | view · |
| 4 | 2026-06-23 | FORM 4 | view · |
| 4 | 2026-06-17 | FORM 4 | view · |
| 4 | 2026-06-08 | FORM 4 | view · |
| 8-K | 2026-05-27 | 8-K | view · |
| 4 | 2026-05-26 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 8-K | 2026-05-13 | 8-K | view · |
| 4 | 2026-05-11 | FORM 4 | view · |
| 8-K | 2026-05-08 | FORM 8-K | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| 4 | 2026-05-04 | FORM 4 | view · |
| DEF 14A | 2026-04-24 | DEF 14A | view · |
| 4 | 2026-04-13 | FORM 4 | view · |
| 8-K | 2026-03-30 | 8-K | view · |
| 4 | 2026-03-20 | FORM 4 | view · |
| 4 | 2026-03-20 | FORM 4 | view · |
| 4 | 2026-03-19 | FORM 4 | view · |
| 4 | 2026-03-16 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-06 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-02-27 | FORM 4 | view · |
| 10-K | 2026-02-24 | 10-K | view · |
| 8-K | 2026-02-24 | 8-K | view · |
| 4 | 2026-02-23 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-12 | FORM 4 | view · |
| 8-K | 2026-02-12 | 8-K | view · |
| 8-K | 2026-01-21 | 8-K | view · |
| 4 | 2026-01-12 | FORM 4 | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2025-12-16 | FORM 4 | view · |
| 4 | 2025-12-16 | FORM 4 | view · |
| 4 | 2025-12-16 | FORM 4 | view · |
| 4 | 2025-12-10 | FORM 4 | view · |
| 4 | 2025-12-08 | FORM 4 | view · |
| 4 | 2025-11-24 | FORM 4 | view · |
About BBIO
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company en…
Options picks · BBIO
ITM + OTM ideas from the latest scanLoading…
Congress trades · BBIO
STOCK Act disclosuresLoading…
SEC filings & insiders · BBIO
EDGAR · liveLoading…
Holders · BBIO
Institutions & insider activityLoading…